Steroids, lidocain and ioxaglic acid modify the viscosity of hyaluronic acid: in vitro study and clinical implications by Thierry Conrozier et al.
Conrozier et al. SpringerPlus  (2016) 5:170 
DOI 10.1186/s40064-016-1762-z
RESEARCH
Steroids, lidocain and ioxaglic acid 
modify the viscosity of hyaluronic acid: in vitro 
study and clinical implications
Thierry Conrozier1* , Jeremy Patarin2, Pierre Mathieu3 and Marguerite Rinaudo4
Abstract 
Background: Viscosupplementaion by intra-articular injection of hyaluronic acid (HA) is a therapeutic modality for 
treating osteoarthritis of the knee, of the hip and less frequently of other joints. During viscosupplementation, it is 
usual to inject other drugs, without knowing whether this association may have a deleterious effect thereon. The 
rheological properties of a viscosupplement are highly dependent on the product [molecular weight × concentra-
tion] of HA. Therefore, any reduction of its viscoelastic properties is related either to a decrease of its concentration or/
and of its molecular weight. The presence of other molecules can create favorable or unfavorable molecular interac-
tions with HA. The objective of the study was to investigate the effect of products, that are commonly associated 
with HA (corticosteroids, lidocain, iodinated contrast media), on the rheological behavior of HA, then to try drawing 
practical conclusions.
Methods: The rheological behavior of both a linear and a cross-linked HA, was studied before and after mixing with 
different volumes (ratio 1:0.5–1:4) of the following compounds: phosphate buffered saline (PBS, as a control), corti-
vazol, triamcinolone hexacetonide, lidocain chlorhydrate and meglumine ioxaglate. The flow curve of the different 
samples was obtained using a measuring method based on a constant shear rate.
Results: Whatever the dilution and the added molecule were, viscosity of the cross-linked viscosupplement 
remained much higher than that of the linear one. Addition of PBS at a ratio 1:1 caused a dramatic decrease (up to 
97.5 %) of HA viscosity. Cortivazol and lidocain had a similar effect than PBS on linear HA. Both were much deleterious 
on cross-linked HA viscosity. Among corticosteroids, triamcinolone decreased much less HA viscosity than cortivazol. 
The effect of meglumine ioxaglate was dose-dependent. Up to a ratio 1:1 viscosity of the linear HA remained above 
the dilution effect. On the cross-linked HA, the deleterious effect of the contrast agent was evident as soon as a ratio 
1:1 and became very marked at 1:2.
Conclusion: HA viscosity varies widely in presence of other molecules. These changes are due to both dilution and 
molecular interactions. This study suggests that addition of other molecules with HA can lead to a major decrease of 
its viscosity. However, provided to respect a maximum ratio of 1:1, the contrast medium and triamcinolone seem to 
have no major deleterious effect on the viscosity level, especially on crosslinked HA. The study also suggests a delete-
rious effect of lidocain on the cross-linked HA. These in vitro data suggest that drugs associations must be avoided 
when they are not essential. However, clinical trials are needed to determine whether these rheological changes may 
have a significant impact on the clinical outcome.
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Background
Viscosupplementation by intra-articular injection(s) of 
hyaluronic acid (HA) is a symptomatic treatment, widely 
used for treating osteoarthritis of the knee (Legré-Boyer 
2015; Bruyère et al. 2014; Bannuru et al. 2015) and, to a 
lesser extent, of the hip, ankle, shoulder, and trapezio-
metacarpal joints. Whatever the joint to be treated, the 
therapeutic protocol is usually the same: 3–5 injections, 
1 week apart, if a linear viscosupplement is used (initial 
structure of the HA molecule) or 1–3 injections when 
using a cross-linked HA. To date cross-linking is the 
main means for increasing the intra-articular residence 
time of the viscosupplement and therefore for reduc-
ing the number of injections (Lindenhayn et  al. 1997; 
Lindqvist et  al. 2002). The injected HA is assumed to 
induce synthesis of endogenous hyaluronic acid (Bagga 
et  al. 2006) which properties are primarily anti-degra-
dative and slightly anti-inflammatory. (du Souich 2014; 
Henrotin et al. 2013; Li et al. 2012). Compared to corti-
costeroids, HA acts in a more prolonged but also more 
delayed way (Bannuru et al. 2009). Therefore, it is com-
mon that a steroid is injected with the HA, for pain relief 
the first 4  weeks during which the HA has not yet had 
time to act. Although a synergistic effect of the two mole-
cules has been suggested (Grecomoro et al. 1992; Ozturk 
et al. 2006; de Campos et al. 2013) the impact of corticos-
teroids on the behavior of HA solutions has never been 
studied. Some practitioners also use a local anesthetic, as 
an analgesic to alleviate pain due to the injection, or in a 
goal to ensure the proper intra-articular needle position 
when the injection is performed using anatomical land-
marks or under ultrasound guidance (Qvistgaard et  al. 
2001). Again there is no data on the impact of local anes-
thetics on the visco-elastic behavior of HA.
Finally, most of the studies assessing the accuracy of 
intra-articular injections conclude at very a high failure 
rate when they are not performed under imaging guid-
ance (Schumacher 2003; Hall 2013; Kurup and Ward 
2010) or by highly trained operators (Mei-Dan et  al. 
2013). For this reason, in all joints, excepted the knee, it 
is advisable to carry out the HA injections under ultra-
sound or radiological control to optimize the chances 
of successful treatment. If the injections are performed 
under fluoroscopic control, iodinated contrast use is 
recommended, but again, the available data, on both the 
effect of the contrast agents on HA and the optimal vol-
ume to be injected, are lacking and do not allow to pro-
pose recommendations in this area.
The objective of this study was to investigate in  vitro 
the impact of different products, frequently associated 
with HA (injectable steroids, local anesthetics and iodi-
nated contrast agent) on the rheological properties of 
HA, then to try drawing practical conclusions.
Methods
Studied devices and drugs
Two viscosupplements were assessed. Hanox-M (Hap-
pyvisc®, LABRHA, Lyon, France) is a linear HA, MW 1.5 
MDa, 31 mg/2 ml, combined with mannitol (3.5 %). Hanox-
M-XL (Happycross®, LABRHA, Lyon, France) is a cross-
linked HA, 35.2 mg/2.2 ml, combined with mannitol (3.5 %).
Two intra-articular corticosteroids were stud-
ied: cortivazol 3.75  mg/1.5  ml (Altim®, Laboratoire 
Sanofi-Aventis, Paris, France) and triamcinolone hex-
acetonide 40 mg/2 ml (Hexatrione®, laboratoires DEXO, 
Saint Cloud, France).
The studied anesthetic was lidocain chlorhydrate 
10 mg/ml (Laboratoire Aguettant, Saint-Fons, France).
The contrast agent was the oxaglic acid, meglumine 
salt, 320  mg Iode/ml (Hexabrix® 320  mg, Laboratoire 
GUERBET, Roissy Charles de Gaulle, France).
Experimental methods
For each of the 2 studied HA, 4 solutions were prepared 
by mixing 1 volume of HA with 0.5, 1, 2, and 4 volumes 
of phosphate buffered saline (PBS), to obtain a control 
solution and to measure only the effect of dilution on the 
rheological properties of HA. Solutions were then made 
by mixing 1 ml of both HA with variable volumes (rang-
ing from 0.5 to 4 ml) of the studied drugs. To get closer 
as possible to the clinical practice, studied ratios were 1:1 
for corticosteroids, 0.5:1, 1:1, 1:2 and 1:4 for the contrast 
agent and 1:1 and 1:2 for the local anaesthetic.
Before starting measurements, the sample was set on 
the bottom plane of the rheometer and squeezed using 
the upper cone at the measurement gap. Product surplus 
was removed with a spatula or syringe. The sample was 
conditioned at a temperature of 25 °C with a precision of 
0.5  °C. The different samples flow curves were obtained 
using a measurement protocol based on a several steps 
of steady flow at constant shear rate. The stress and shear 
viscosity values were monitored since the flow was con-
sidered established at each step.
To compare the direct effect of the solvent on the dilu-
tion, the flow curves of each HA were also established 
with different products for a same dilution. The results 
were given with an accuracy of 10 % due to the precision 
of the measurement system.
Results
Influence of dilution
Diluted by PBS, linear HA preserved its shear-thinning 
behaviour and exhibited a non-Newtonian plateau. Nev-
ertheless, viscosity levels decreased very significantly as 
soon as a 1:0.5 ratio, as shown by a 13 % residual viscos-
ity, reaching only 2.5  % at a 1:1 ratio, at gradient speed 
0.01 s−1 (Fig. 1; Table 1).
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The rheological behavior of the cross-linked HA 
remained non-Newtonian in all cases.
However viscosity levels decreased with increasing 
dilution, but in a lower proportion than for the linear 
product, in particular at ratio 1:0.5 and 1:1, where the vis-
cosity at 0.01 s−1 was still 39 and 20 % of the non-diluted 
viscosity respectively (Fig.  2; Table  1). The cross-linked 
HA, initially much more viscous than the linear HA, 
maintained a residual viscosity at a dilution of 1/2 twice 
as great as the undiluted linear product.
This experience shew clearly that dilution is a very 
important factor, greatly for the viscosities of linear HA 
solutions and lesser for cross-linked HA solutions.
Influence of addition of different diluents
Table  2 and Fig.  3 summarize the effect of the different 
molecules added to the linear viscosupplement. They 
point out the major effect of dilution on the HA rheologi-
cal properties regardless of the added molecule. Cortiva-
zol and lidocain have substantially the same effect as the 
stock dilution with PBS. However ioxaglic acid and even 
more triamcinolone hexacetonide reduced a much lower 
the viscosity of the HA solution, up to a 1:1 ratio.
Table  3 and Fig.  4 summarize the effect of the differ-
ent molecules added to the cross-linked HA. The dilution 
effect was much less pronounced because of cross-link-
ing, holding the cohesion of the gel in aqueous media 
up to a certain limit. Here again, a significantly different 
effect of the two tested corticosteroids was noticed. Tri-
amcinolone hexacetonide reduced moderately the viscos-
ity unlike cortivazol, whereas the effect of the latter was 
roughly similar than that of PBS.
In contrast, lidocain hydrochloride and, even more iox-
aglic acid, had a more marked effect on the cross-linked 
HA viscosity than on the linear one, most likely as a 
result of secondary interactions with HA due to the ionic 
charge and/or pH.
The effect of the iodinated contrast agent on the viscos-
ity was clearly volume-dependent, and depended on the 
formulation of the viscosupplement. Up to a ratio of 1:1, 
the viscosity of the linear HA remained above the dilu-
tion effect. Beyond this ratio, ioxaglic acid had a similar 
effect to that of the buffer. On the cross-linked HA, the 
deleterious effect of the contrast agent appeared from 
1:1 and became very significant at a 1:2 ratio. Visual 
observation shew that, regardless of the HA, there was 
a separation phase for the 1:4 ratio. At all dilution levels 
and regardless of the diluents, the viscosity of the cross-
linked viscosupplement remained much higher than that 
of the linear HA.
Discussion
The main lesson that can be drawn from this in  vitro 
study is that addition of any other product to hyalu-
ronic acid may greatly modify its rheological behaviour. 
Indeed, the rheological properties of HA are highly 
dependent on the product [concentration  ×  molecu-
lar weight] of the latter (Fouissac et al. 1993). The effect 
of dilution is not negligible, in particular on the linear 
viscosupplement whose cohesion is greatly affected as 
soon as this dilution reaches a ratio of 1:0.5. The dilution 
of the drug is suspected to reduce its effectiveness. It is 
the reason why, it is usually advised to carefully remove 
Fig. 1 Flow curve of linear hyaluronic acid diluted with increasing 
volumes of PBS. Viscosity is given in Pa.s according to the shear rate 
s−1. HA hyaluronic acid, PBS phosphate buffer saline
Table 1 Viscosity (Pa.s) of  hyaluronic acid (HA) solutions 
at  0.01  s−1 and  25  °C according to  dilution by  phosphate 
buffer (PBS)
HA structure Viscosity at 0.01 s−1 (Pa.s)
Initial Ratio 1/0.5 Ratio 1/1 Ratio 1/2 Ratio 1/4
Linear HA 77 10 2 1 0.07
Cross-linked HA 2560 1010 520 130 15
Fig. 2 Flow curve of cross-linked hyaluronic acid diluted with 
increasing volumes of PBS. Viscosity is given in Pa.s according to the 
shear rate s−1. HA hyaluronic acid, PBS phosphate buffer saline
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any synovial effusion prior to an intra-articular injection 
(Maricar et al. 2013; Uthman et al. 2003). We had previ-
ously shown that adding a linear HA in an equivalent vol-
ume of an osteoarthritic synovial fluid was not sufficient 
to increase the viscosity of the latter. However a signifi-
cant increase of the synovial fluid viscosity was observed 
when adding an equivalent volume and concentration of 
a cross-linked HA, suggesting the importance of interac-
tion between exogenous HA and the three-dimensional 
network constituted by HA and synovial fluid proteins 
(Mathieu et al. 2009).
The second lesson is that the 2 tested corticosteroids, 
both frequently used in the treatment of OA, have dif-
ferential effects on the viscosupplement properties. Cor-
tivazol has no significant impact on HA properties. The 
decrease in viscosity is only slightly greater than that 
obtained with PBS. Conversely triamcinolone hexaceto-
nide seems to stabilize the viscosupplement, suggesting 
that the increase in viscosity, results from the existence of 
favourable interactions between HA and triamcinolone. 
Thus, if a corticosteroid should be injected together with 
a viscosupplement, it seems logical to favour the second 
rather than the first, as long as it has not been demon-
strated this does not affect the clinical outcome.
Similarly, lidocain, which cytotoxicity on chondro-
cytes is highlighted by numerous recent works (Rao et al. 
2014; Ravnihar et  al. 2014; Rahnama et  al. 2013), does 
not seem to be used in combination with HA, despite 
the latter decreases its cytotoxicity (Onur et al. 2013). In 
our experiments lidocain has a deleterious effect on the 
cross-linked HA. Its effect on linear HA solution appears 
less clearly, probably because the simple dilution already 
causes a major loss of viscosity.
Finally, this study suggests that, in case of fluoroscopic 
guidance, the amount of iodinated contrast media must 
be as low as possible. In a ratio of 1:0.5, meglumine iox-
aglate does not alter significantly the viscosity of the 
cross-linked HA, but as soon a ratio of 1: 1 (i.e. in clini-
cal practice 2 ml of contrast for 2 ml of HA) the viscoe-
lastic performances decrease dramatically, much beyond 
the dilution effect. For linear HA, viscosity of the mixture 
remains somewhat higher than that obtained with the 
PBS until a 1:2 ratio. Anyway it seems to us logical not 
to perform viscosupplementation during an arthrogra-
phy for diagnosis purposes and to use only the minimum 
dose of contrast agent required to assert the intra-articu-
lar needle position (i.e. most of the time less than 1 ml). 
In a cohort of 50 patients with talo-crural OA (Conro-
zier et al. 2014), the success rate was 100 % among those 
injected under ultrasound control versus only 64.5  % 
among those injected using fluoroscopy guidance, lead-
ing to the hypothesis that this difference may result to the 
use of a contrast agent.
The main limitation of our study is due to the limited 
choice of the studied viscosupplements. Indeed, visco-
supplements differ widely from each other so the results 
of clinical trials with a particular viscosupplement cannot 
be systematically extrapolated to others (Henrotin et  al. 
2015). It is possible that the results would be slightly differ-
ent with viscosupplements of different molecular weight 
and or concentration, with other methods of cross-linking, 
or with viscosupplements not containing mannitol, which 
protects HA from reactive oxygen species-induced degra-
dation (Rinaudo et al. 2014; Conrozier et al. 2014).
Prospective clinical trials are therefore needed to con-
firm or refute this hypothesis and to determine if the 
Table 2 Influence of the diluent (in a ratio 1:1) on viscosity of HA solutions at 0.01 s−1 and 25 °C
HA hyaluronic acid, TH triamcinolone hexacetonide, IA ioxaglic acid, PBS phosphate buffer solution
HA structure Viscosity at 0.01 s−1 (Pa.s)
HA HA + PBS HA + cortivazol HA + TH HA + lidocain HA + IA
Linear HA 79 2 3 17 5 20
Cross-linked HA 2560 520 576 1450 306 359
Fig. 3 Flow curve of linear hyaluronic acid mixed with different prod-
ucts (ratio 1:1). HA hyaluronic acid, TH triamcinolone hexacetonide, IA 
ioxaglic acid, PBS phosphate buffer saline
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in vitro variations have an impact on the clinical outcome 
of viscosupplementation.
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